25I.F IMMUPHARMA PLC LS-01

Healthcare Biotechnology Frankfurt Exchange
0.0155 EUR
Close of Nov 11, 2026
0.0155 0.1010
Market cap
EUR 9.69M
P/E
-
P/B
5.01x
ROE
-263.2%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the fiscal year ending Dec 2025.

Is 25I.F undervalued?

Graham number

The Graham number of IMMUPHARMA PLC LS-01 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

IMMUPHARMA PLC LS-01 fundamental analysis

No fundamental analysis for IMMUPHARMA PLC LS-01 yet.

IMMUPHARMA PLC LS-01 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About IMMUPHARMA PLC LS-01

ImmuPharma plc, together with its subsidiaries, engages in the research, development, and commercialization of peptide-based therapeutics for autoimmune diseases, infectious diseases, and metabolic disorders in the United Kingdom and internationally. It develops P140, a peptide-based therapy, which is in clinical trial for the treatment of autoimmune and inflammatory diseases, as well as various therapeutic areas, including dermatology, gastroenterology, rheumatology, endocr…

Full company profile